Abstract
We report the results of a randomized, double-blind, placebo-controlled, 16-week study to evaluate the efficacy and safety of ropinirole, 0.75 to 15.0 mg/day, as an adjunct to levodopa. A total of 243 patients were randomly assigned into placebo or ropinirole groups. The mean (standard deviation) dose of ropinirole at endpoint was 7.12 (2.88) mg/day. The primary endpoint - the mean reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) total motor score - was significantly greater for the ropinirole group than the placebo group (-9.5 vs. -4.5, P = 0.00001). The mean reduction in the UPDRS total activities of daily living (ADL) score was also significantly greater for ropinirole than for placebo (-2.7 vs. -1.0, P = 0.0002). The percentage of patients showing at least a 20% reduction in the percentage of time spent "off was significantly greater for the ropinirole group than for the placebo group (58.7% vs. 38.6%, P = 0.030). A total of 84.3 and 65.6% of the patients experienced adverse events while receiving ropinirole or placebo, respectively. The results showed that ropinirole was more effective than placebo in improving motor function and ADL when used as an adjunct to levodopa in patients with advanced Parkinson's disease.
| Original language | English |
|---|---|
| Pages (from-to) | 1860-1865 |
| Number of pages | 6 |
| Journal | Movement Disorders |
| Volume | 22 |
| Issue number | 13 |
| DOIs | |
| Publication status | Published - Oct 15 2007 |
Fingerprint
Keywords
- L-dopa
- Parkinson's disease
- Randomized controlled study
- Ropinirole
- Treatment
ASJC Scopus subject areas
- Clinical Neurology
- Neuroscience(all)
Cite this
Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease : STRONG study. / Mizuno, Yoshikuni; Abe, Takashi; Hasegawa, Kazuko; Kuno, Sadako; Kondo, Tomoyoshi; Yamamoto, Mitsutoshi; Nakashima, Mitsuyoshi; Kanazawa, Ichiro; Honma, S.; Baba, M.; Toyoshima, I.; Onodera, H.; Nakano, I.; Nomura, H.; Yamane, K.; Tanaka, S.; Yoshino, H.; Ueki, A.; Yokochi, F.; Tamaki, M.; Yokochi, M.; Utsumi, H.; Iwata, M.; Kawai, M.; Hashimoto, T.; Teramoto, J.; Atsumi, T.; Takahashi, M.; Mitsui, Y.; Matsubara, T.; Azuma, T.; Matsumoto, S.; Tachibana, H.; Hiyama, K.; Abe, Koji; Nakashima, K.; Kohhira, I.; Nomoto, M.; Yamada, T.
In: Movement Disorders, Vol. 22, No. 13, 15.10.2007, p. 1860-1865.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease
T2 - STRONG study
AU - Mizuno, Yoshikuni
AU - Abe, Takashi
AU - Hasegawa, Kazuko
AU - Kuno, Sadako
AU - Kondo, Tomoyoshi
AU - Yamamoto, Mitsutoshi
AU - Nakashima, Mitsuyoshi
AU - Kanazawa, Ichiro
AU - Honma, S.
AU - Baba, M.
AU - Toyoshima, I.
AU - Onodera, H.
AU - Nakano, I.
AU - Nomura, H.
AU - Yamane, K.
AU - Tanaka, S.
AU - Yoshino, H.
AU - Ueki, A.
AU - Yokochi, F.
AU - Tamaki, M.
AU - Yokochi, M.
AU - Utsumi, H.
AU - Iwata, M.
AU - Kawai, M.
AU - Hashimoto, T.
AU - Teramoto, J.
AU - Atsumi, T.
AU - Takahashi, M.
AU - Mitsui, Y.
AU - Matsubara, T.
AU - Azuma, T.
AU - Matsumoto, S.
AU - Tachibana, H.
AU - Hiyama, K.
AU - Abe, Koji
AU - Nakashima, K.
AU - Kohhira, I.
AU - Nomoto, M.
AU - Yamada, T.
PY - 2007/10/15
Y1 - 2007/10/15
N2 - We report the results of a randomized, double-blind, placebo-controlled, 16-week study to evaluate the efficacy and safety of ropinirole, 0.75 to 15.0 mg/day, as an adjunct to levodopa. A total of 243 patients were randomly assigned into placebo or ropinirole groups. The mean (standard deviation) dose of ropinirole at endpoint was 7.12 (2.88) mg/day. The primary endpoint - the mean reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) total motor score - was significantly greater for the ropinirole group than the placebo group (-9.5 vs. -4.5, P = 0.00001). The mean reduction in the UPDRS total activities of daily living (ADL) score was also significantly greater for ropinirole than for placebo (-2.7 vs. -1.0, P = 0.0002). The percentage of patients showing at least a 20% reduction in the percentage of time spent "off was significantly greater for the ropinirole group than for the placebo group (58.7% vs. 38.6%, P = 0.030). A total of 84.3 and 65.6% of the patients experienced adverse events while receiving ropinirole or placebo, respectively. The results showed that ropinirole was more effective than placebo in improving motor function and ADL when used as an adjunct to levodopa in patients with advanced Parkinson's disease.
AB - We report the results of a randomized, double-blind, placebo-controlled, 16-week study to evaluate the efficacy and safety of ropinirole, 0.75 to 15.0 mg/day, as an adjunct to levodopa. A total of 243 patients were randomly assigned into placebo or ropinirole groups. The mean (standard deviation) dose of ropinirole at endpoint was 7.12 (2.88) mg/day. The primary endpoint - the mean reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) total motor score - was significantly greater for the ropinirole group than the placebo group (-9.5 vs. -4.5, P = 0.00001). The mean reduction in the UPDRS total activities of daily living (ADL) score was also significantly greater for ropinirole than for placebo (-2.7 vs. -1.0, P = 0.0002). The percentage of patients showing at least a 20% reduction in the percentage of time spent "off was significantly greater for the ropinirole group than for the placebo group (58.7% vs. 38.6%, P = 0.030). A total of 84.3 and 65.6% of the patients experienced adverse events while receiving ropinirole or placebo, respectively. The results showed that ropinirole was more effective than placebo in improving motor function and ADL when used as an adjunct to levodopa in patients with advanced Parkinson's disease.
KW - L-dopa
KW - Parkinson's disease
KW - Randomized controlled study
KW - Ropinirole
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=36248982041&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36248982041&partnerID=8YFLogxK
U2 - 10.1002/mds.21313
DO - 10.1002/mds.21313
M3 - Article
C2 - 17618525
AN - SCOPUS:36248982041
VL - 22
SP - 1860
EP - 1865
JO - Movement Disorders
JF - Movement Disorders
SN - 0885-3185
IS - 13
ER -